302 related articles for article (PubMed ID: 9457812)
1. Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.
Rajkumar SV; Buckner JC; Schomberg PJ; Cascino TL; Burch PA; Dinapoli RP
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):297-302. PubMed ID: 9457812
[TBL] [Abstract][Full Text] [Related]
2. Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas.
Rajkumar SV; Buckner JC; Schomberg PJ; Pitot HC; Ingle JN; Cascino TL
Neurosurgery; 1999 Jan; 44(1):67-73. PubMed ID: 9894965
[TBL] [Abstract][Full Text] [Related]
3. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.
Buckner JC; Schomberg PJ; McGinnis WL; Cascino TL; Scheithauer BW; O'Fallon JR; Morton RF; Kuross SA; Mailliard JA; Hatfield AK; Cole JT; Steen PD; Bernath AM
Cancer; 2001 Jul; 92(2):420-33. PubMed ID: 11466698
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma.
Rajkumar SV; Buckner JC; Schomberg PJ; Reid JM; Bagniewski PJ; Ames MM; Cascino TL; Marks RS
Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):969-75. PubMed ID: 9869217
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas.
Brandes AA; Scelzi E; Zampieri P; Rigon A; Rotilio A; Amista P; Berti F; Fiorentino MV
Am J Clin Oncol; 1997 Aug; 20(4):364-7. PubMed ID: 9256890
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Raizer JJ; Malkin MG; Kleber M; Abrey LE
Neuro Oncol; 2004 Jul; 6(3):247-52. PubMed ID: 15279717
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma.
Buckner JC; Brown LD; Kugler JW; Cascino TL; Krook JE; Mailliard JA; Kardinal CG; Tschetter LK; O'Fallon JR; Scheithauer BW
J Neurosurg; 1995 Mar; 82(3):430-5. PubMed ID: 7861221
[TBL] [Abstract][Full Text] [Related]
8. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
Prados MD; Larson DA; Lamborn K; McDermott MW; Sneed PK; Wara WM; Chang SM; Mack EE; Krouwer HG; Chandler KL; Warnick RE; Davis RL; Rabbitt JE; Malec M; Levin VA; Gutin PH; Phillips TL; Wilson CB
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):57-63. PubMed ID: 9422558
[TBL] [Abstract][Full Text] [Related]
9. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
10. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma.
Dinapoli RP; Brown LD; Arusell RM; Earle JD; O'Fallon JR; Buckner JC; Scheithauer BW; Krook JE; Tschetter LK; Maier JA
J Clin Oncol; 1993 Jul; 11(7):1316-21. PubMed ID: 8315428
[TBL] [Abstract][Full Text] [Related]
11. Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
Jeremic B; Grujicic D; Antunovic V; Djuric L; Stojanovic M; Shibamoto Y
Int J Radiat Oncol Biol Phys; 1994 Dec; 30(5):1179-85. PubMed ID: 7961028
[TBL] [Abstract][Full Text] [Related]
12. The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma.
Kleinberg L; Grossman SA; Piantadosi S; Zeltzman M; Wharam M
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):535-43. PubMed ID: 10348282
[TBL] [Abstract][Full Text] [Related]
13. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.
Chang CH; Horton J; Schoenfeld D; Salazer O; Perez-Tamayo R; Kramer S; Weinstein A; Nelson JS; Tsukada Y
Cancer; 1983 Sep; 52(6):997-1007. PubMed ID: 6349785
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
15. Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study.
Hochberg F; Prados M; Russell C; Weissman D; Evans R; Cook P; Burton G; Eisenberg PD; Valenzuela R; Verkh L
J Neurooncol; 1997 Mar; 32(1):45-55. PubMed ID: 9049862
[TBL] [Abstract][Full Text] [Related]
16. Early chemotherapy and concurrent radio-chemotherapy in high grade glioma.
Brandes AA; Rigon A; Zampieri P; Scelzi E; Amistà P; Berti F; Rotilio A; Gardiman M; Fiorentino MV
J Neurooncol; 1996 Dec; 30(3):247-55. PubMed ID: 8943100
[TBL] [Abstract][Full Text] [Related]
17. Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas.
Rao RD; Thomé SD; O'Fallon J; Earle JD; Dinapoli RP; Buckner JC
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):376-84. PubMed ID: 12023142
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
Mittelman A; Huberman M; Puccio C; Fallon B; Tessitore J; Savona S; Eyre R; Gafney E; Wick M; Skelos A
Cancer; 1990 Aug; 66(4):664-9. PubMed ID: 2386896
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.
Fine HA; Wen PY; Maher EA; Viscosi E; Batchelor T; Lakhani N; Figg WD; Purow BW; Borkowf CB
J Clin Oncol; 2003 Jun; 21(12):2299-304. PubMed ID: 12805330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
